id,disease_progression_status,survival_status,clinical_response_rate_target_lasion,clinical_response_rate_non_target_lasion,clinical_response_rate_new_lasion,clinical_response_rate_result,radiological_response_rate_target_lasion,radiological_response_rate_non_target_lasion,radiological_response_rate_new_lasion,radiological_response_rate_result,pathological_response_rate_target_lasion,pathological_response_rate_non_target_lasion,pathological_response_rate_new_lasion,pathological_response_rate_result,time,registration_number,laterality,current_chemo_protocol,chemo_starting_date,chemo_cycle_no,chemo_detail,disease_progression_status_date,pfs,survival_status_date,overall_survival,clinical_response_rate_date,radiological_response_rate_date,pathological_response_rate_date,cancer_type,patient_id_id,patient_id_socio_economic_status_name,patient_id_unique_id,patient_id_name,patient_id_phone,patient_id_date_of_birth,patient_id_gender,patient_id_blood_group,patient_id_area,patient_id_police_station,patient_id_district,doctor_id_name,center_id_name,grade_name,line_of_treatment_name,diagnosis_disease_group_name,diagnosis_subgroup_diagnosis_disease_group_name,diagnosis_subgroup_name,diagnosis_primary_site_name,diagnosis_laterility_name,patient_id_socio_economic_status,grade,disease_progression_status_name,survival_status_name,clinical_response_rate_target_lasion_name,clinical_response_rate_non_target_lasion_name,clinical_response_rate_new_lasion_name,clinical_response_rate_result_name,radiological_response_rate_target_lasion_name,radiological_response_rate_non_target_lasion_name,radiological_response_rate_new_lasion_name,radiological_response_rate_result_name,diagnosis_laterility,line_of_treatment,diagnosis_subgroup,pathological_response_rate_target_lasion_name,pathological_response_rate_non_target_lasion_name,pathological_response_rate_new_lasion_name,pathological_response_rate_result_name,diagnosis_disease_group,diagnosis_primary_site,name,value,unit,date,patient_observation_id
116,,,,,,,,,,,,,,,2024-05-14T15:25:18+06:00,BSH - R180304131,B/Lateral,Tucatinib + Capecitabine,,,"NACT, C1 started from 22.03.2018 with AC, C4 completed up to 24.05.2018. C8 with Paclitaxel up to
16.08.2018>
• Lapatinib and XELODA since FEB 2019, up to March'2020 (Discontinued)> Local recurrence and Left
breast primary detected (March 21)
• 2nd line Docetaxel q3w+ Weekly Trastuzumab, C1D1 from 21.03.2021, C2D1 due on 11.04.2021 (Delayed
due to COVID-19, received on 5.06.21), Cycle 6 with Docetaxel completed on 28.08.2021> Week13 with
Trastuzumab completed on 18.09.2021> Maintenance 1 with Trastuzumab from on 09.10.2021, M9 received
on 27.03.2022, Lapatinib + Capecitabine added after M9 due to PD (Pt could not afford TDM1)> M12 up to on 29.05.22> PD
• Started TDM1 Cycle 1 from 20.06.2022. C8 completed on 3.12.22, Cycle 9 is due on 24.12.2022 (Hold due to
PD)>
• Switch to Tucatinib + Capecitabine from Jan 23 (After 2 weeks stop Tucatinib), resatrted from 1.03.2023
and received 7 weeks of Tucatinib so far up to 11.06.2023",2023-06-15,,2023-06-18,,2023-06-15,,,Breast,112,Upper middle class,BSBSC-240000112,NURJAHAN BEGUM,1737200182,1948-03-13,Female,,,,,Dr Md Arifur Rahman,BSH,2.0,,C50- Malignant neoplasm of breast,C50- Malignant neoplasm of breast,C50.5- Lower-outer quadrant of breast,Breast,Bilateral,,,Progressed,Alive,PD,,,,,,,,,,,,,,,,,,,,,
